$RGNX News

REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript

Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call

Full Transcript: Regenxbio Q2 2026 Earnings Call

Mizuho Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $22

Regenxbio stock gains on positive gene therapy trial data

Reported Earlier, REGENXBIO Presents Three-Year Sura-Vec Data Showing Majority Of NPDR Participants Achieved Greater Than 2-Step DRSS Improvement, No Vision-Threatening Events

REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids

REGENXBIO Announces $39M Settlement With Sarepta Resolving All Elevidys Patent Litigation

REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

REGENXBIO to Participate in Upcoming Investor Conferences

Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome

HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $21

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street

FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial

Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity

Baird Maintains Outperform on Regenxbio, Lowers Price Target to $29

RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy

Why Did RGNX Stock Crash Today?

REGENXBIO Shares Plunge After FDA Places Clinical Hold on RGX-121